Skip to main content
Top
Published in: Infection 6/2015

Open Access 01-12-2015 | Original Paper

Clinical and economic burden of community-acquired pneumonia in the Veterans Health Administration, 2011: a retrospective cohort study

Authors: John M. McLaughlin, Maribeth H. Johnson, Stephen A. Kagan, Stephanie L. Baer

Published in: Infection | Issue 6/2015

Login to get access

Abstract

Purpose

The burden of community-acquired pneumonia (CAP) is not well described in the US Veterans Health Administration (VHA).

Methods

CAP was defined as having a pneumonia diagnosis with evidence of chest X-ray, and no evidence of prior (90 days) hospitalization/long-term care. We calculated incidence rates of adult CAP occurring in inpatient or outpatient VHA settings in 2011. We also estimated the proportion of VHA CAP patients who were hospitalized, were readmitted within 30 days of hospital discharge, and died (any cause) in the year following diagnosis. Incremental costs during the 90 days following a CAP diagnosis were estimated from the perspective of the VHA.

Results

In 2011, 34,101 Veterans developed CAP (35,380 episodes) over 7,739,757 VHA person-years. Median age of CAP patients was 65 years (95 % male). CAP incidence rates were higher for those aged ≥50 years. A majority of Veterans aged 50–64 (53 %) and ≥65 (66 %) years had ≥1 chronic medical (moderate risk) or immunocompromising (high risk) condition. Compared to those at low-risk (healthy), moderate- and high-risk Veterans were >3 and >6 times more likely to develop CAP, respectively. The percentage of CAP patients who were hospitalized was 45 %, ranging from 12 % (age 18–49, low risk) to 57 % (age ≥65, high risk). One-year all-cause mortality rates ranged from 1 % (age 18–49, low risk) to 36 % (age ≥65, high risk). Annual VHA medical expenditure related to CAP was estimated to be $750 million (M) ($415M for those aged ≥65 years).

Conclusion

A focus on CAP prevention among older Veterans and those with comorbid or immunocompromising conditions is important.
Appendix
Available only for authorised users
Literature
1.
go back to reference Centers for Disease Control and Prevention. The Pink Book: Pneumococcal Disease, 12th Edition Second Printing May 2012. Atlanta: Centers for Disease Control and Prevention, National Center for Injury Prevention and Control; 2012. Centers for Disease Control and Prevention. The Pink Book: Pneumococcal Disease, 12th Edition Second Printing May 2012. Atlanta: Centers for Disease Control and Prevention, National Center for Injury Prevention and Control; 2012.
2.
go back to reference Song JH, Thamlikitkul V, Hsueh PR. Clinical and economic burden of community-acquired pneumonia amongst adults in the Asia-Pacific region. Int J Antimicrob Agents. 2011;38:108–17.PubMed Song JH, Thamlikitkul V, Hsueh PR. Clinical and economic burden of community-acquired pneumonia amongst adults in the Asia-Pacific region. Int J Antimicrob Agents. 2011;38:108–17.PubMed
3.
go back to reference Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012;67:71–9.CrossRefPubMed Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012;67:71–9.CrossRefPubMed
4.
go back to reference Niederman MS. How do we optimize outcomes for patients with severe community-acquired pneumonia? Intensive Care Med. 2002;28:1003–5.CrossRefPubMed Niederman MS. How do we optimize outcomes for patients with severe community-acquired pneumonia? Intensive Care Med. 2002;28:1003–5.CrossRefPubMed
5.
go back to reference Niederman MS. Community-acquired pneumonia: the U.S. perspective. Semin Respir Crit Care Med. 2009;30:179–88.CrossRefPubMed Niederman MS. Community-acquired pneumonia: the U.S. perspective. Semin Respir Crit Care Med. 2009;30:179–88.CrossRefPubMed
6.
go back to reference Niederman MS, et al. The cost of treating community-acquired pneumonia. Clin Ther. 1998;20:820–37.CrossRefPubMed Niederman MS, et al. The cost of treating community-acquired pneumonia. Clin Ther. 1998;20:820–37.CrossRefPubMed
7.
go back to reference File TM Jr, Marrie TJ. Burden of community-acquired pneumonia in North American adults. Postgrad Med. 2010;122:130–41.CrossRefPubMed File TM Jr, Marrie TJ. Burden of community-acquired pneumonia in North American adults. Postgrad Med. 2010;122:130–41.CrossRefPubMed
8.
go back to reference Isea-Pena MC, et al. Risk factors and clinical significance of invasive infections caused by levofloxacin-resistant Streptococcus pneumoniae. Infection. 2013;41:935–9.CrossRefPubMed Isea-Pena MC, et al. Risk factors and clinical significance of invasive infections caused by levofloxacin-resistant Streptococcus pneumoniae. Infection. 2013;41:935–9.CrossRefPubMed
9.
go back to reference Melzer M, Welch C. 30-day mortality in UK patients with bacteraemic community-acquired pneumonia. Infection. 2013;41:1005–11.CrossRefPubMed Melzer M, Welch C. 30-day mortality in UK patients with bacteraemic community-acquired pneumonia. Infection. 2013;41:1005–11.CrossRefPubMed
10.
go back to reference Colice GL, et al. Treatment costs of community-acquired pneumonia in an employed population. Chest. 2004;125:2140–5.CrossRefPubMed Colice GL, et al. Treatment costs of community-acquired pneumonia in an employed population. Chest. 2004;125:2140–5.CrossRefPubMed
11.
go back to reference Dixon RE. Economic costs of respiratory tract infections in the United States. Am J Med. 1985;78:45–51.CrossRefPubMed Dixon RE. Economic costs of respiratory tract infections in the United States. Am J Med. 1985;78:45–51.CrossRefPubMed
12.
go back to reference Mandell LA. Epidemiology and etiology of community-acquired pneumonia. Infect Dis Clin North Am. 2004;18:761–76 (vii).CrossRefPubMed Mandell LA. Epidemiology and etiology of community-acquired pneumonia. Infect Dis Clin North Am. 2004;18:761–76 (vii).CrossRefPubMed
13.
go back to reference Centers for Disease Control and Prevention, National Center for Health Statistics, 2010 National Hospital Discharge Survey. Atlanta: Centers for Disease Control and Prevention, National Center for Injury Prevention and Control; 2010. Centers for Disease Control and Prevention, National Center for Health Statistics, 2010 National Hospital Discharge Survey. Atlanta: Centers for Disease Control and Prevention, National Center for Injury Prevention and Control; 2010.
14.
go back to reference Welte T. Risk factors and severity scores in hospitalized patients with community-acquired pneumonia: prediction of severity and mortality. Eur J Clin Microbiol Infect Dis. 2012;31:33–47.CrossRefPubMed Welte T. Risk factors and severity scores in hospitalized patients with community-acquired pneumonia: prediction of severity and mortality. Eur J Clin Microbiol Infect Dis. 2012;31:33–47.CrossRefPubMed
15.
go back to reference Agha Z, et al. Are patients at Veterans Affairs medical centers sicker? A comparative analysis of health status and medical resource use. Arch Intern Med. 2000;160:3252–7.CrossRefPubMed Agha Z, et al. Are patients at Veterans Affairs medical centers sicker? A comparative analysis of health status and medical resource use. Arch Intern Med. 2000;160:3252–7.CrossRefPubMed
16.
go back to reference Kazis LE, et al. Health-related quality of life in patients served by the Department of Veterans Affairs: results from the Veterans Health Study. Arch Intern Med. 1998;158:626–32.CrossRefPubMed Kazis LE, et al. Health-related quality of life in patients served by the Department of Veterans Affairs: results from the Veterans Health Study. Arch Intern Med. 1998;158:626–32.CrossRefPubMed
17.
go back to reference American Thoracic Society & Infectious Diseases Society of. America, Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388–416.CrossRef American Thoracic Society & Infectious Diseases Society of. America, Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171:388–416.CrossRef
18.
go back to reference Broulette J, et al. The incidence rate and economic burden of community-acquired pneumonia in a working-age population. Am Health Drug Benefits. 2013;6:494–503.PubMedCentralPubMed Broulette J, et al. The incidence rate and economic burden of community-acquired pneumonia in a working-age population. Am Health Drug Benefits. 2013;6:494–503.PubMedCentralPubMed
19.
go back to reference Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1997; 46: 1–24. Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 1997; 46: 1–24.
20.
go back to reference Kyaw MH, et al. The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis. 2005;192:377–86.CrossRefPubMed Kyaw MH, et al. The influence of chronic illnesses on the incidence of invasive pneumococcal disease in adults. J Infect Dis. 2005;192:377–86.CrossRefPubMed
21.
go back to reference Weycker D, et al. Clinical and economic burden of pneumococcal disease in older US adults. Vaccine. 2010;28:4955–60.CrossRefPubMed Weycker D, et al. Clinical and economic burden of pneumococcal disease in older US adults. Vaccine. 2010;28:4955–60.CrossRefPubMed
22.
23.
go back to reference Wagner TH, Chen S, Barnett PG. Using average cost methods to estimate encounter-level costs for medical-surgical stays in the VA. Med Care Res Rev. 2003;60:15S–36S.CrossRefPubMed Wagner TH, Chen S, Barnett PG. Using average cost methods to estimate encounter-level costs for medical-surgical stays in the VA. Med Care Res Rev. 2003;60:15S–36S.CrossRefPubMed
24.
go back to reference Chi RC, Reiber GE, Neuzil KM. Influenza and pneumococcal vaccination in older veterans: results from the behavioral risk factor surveillance system. J Am Geriatr Soc. 2006;54:217–23.CrossRefPubMed Chi RC, Reiber GE, Neuzil KM. Influenza and pneumococcal vaccination in older veterans: results from the behavioral risk factor surveillance system. J Am Geriatr Soc. 2006;54:217–23.CrossRefPubMed
25.
go back to reference US Food and Drug Administration, FDA expands use of Prevnar 13 vaccine for people ages 50 and older. US Department of Health and Human Services: Silver Spring; 2011. US Food and Drug Administration, FDA expands use of Prevnar 13 vaccine for people ages 50 and older. US Department of Health and Human Services: Silver Spring; 2011.
26.
go back to reference Tomczyk S, et al. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged >/=65 Years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2014;63:822–5.PubMed Tomczyk S, et al. Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine Among Adults Aged >/=65 Years: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2014;63:822–5.PubMed
27.
go back to reference Bonten MJ, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372:1114–25.CrossRefPubMed Bonten MJ, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372:1114–25.CrossRefPubMed
28.
go back to reference Isturiz, R. and C. Webber, Prevention of Adult Pneumococcal Pneumonia With the 13-Valent Pneumococcal Conjugate Vaccine: CAPiTA, the Community-Acquired Pneumonia Immunization Trial in Adults. Human Vaccine Immunotherap. 2015; 11. ( in press). Isturiz, R. and C. Webber, Prevention of Adult Pneumococcal Pneumonia With the 13-Valent Pneumococcal Conjugate Vaccine: CAPiTA, the Community-Acquired Pneumonia Immunization Trial in Adults. Human Vaccine Immunotherap. 2015; 11. ( in press).
29.
go back to reference Jackson ML, et al. The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin Infect Dis. 2004;39:1642–50.CrossRefPubMed Jackson ML, et al. The burden of community-acquired pneumonia in seniors: results of a population-based study. Clin Infect Dis. 2004;39:1642–50.CrossRefPubMed
30.
go back to reference Yu H, et al. Clinical and economic burden of community-acquired pneumonia in the Medicare fee-for-service population. J Am Geriatr Soc. 2012;60:2137–43.PubMed Yu H, et al. Clinical and economic burden of community-acquired pneumonia in the Medicare fee-for-service population. J Am Geriatr Soc. 2012;60:2137–43.PubMed
31.
go back to reference Hynes DM, et al. Veterans’ access to and use of medicare and veterans affairs health care. Med Care. 2007;45:214–23.CrossRefPubMed Hynes DM, et al. Veterans’ access to and use of medicare and veterans affairs health care. Med Care. 2007;45:214–23.CrossRefPubMed
32.
go back to reference Petersen LA, et al. Relationship between clinical conditions and use of Veterans Affairs health care among Medicare-enrolled veterans. Health Serv Res. 2010;45:762–91.PubMedCentralCrossRefPubMed Petersen LA, et al. Relationship between clinical conditions and use of Veterans Affairs health care among Medicare-enrolled veterans. Health Serv Res. 2010;45:762–91.PubMedCentralCrossRefPubMed
33.
go back to reference Liu CF, et al. Use of outpatient care in Veterans Health Administration and Medicare among veterans receiving primary care in community-based and hospital outpatient clinics. Health Serv Res. 2010;45:1268–86.PubMedCentralCrossRefPubMed Liu CF, et al. Use of outpatient care in Veterans Health Administration and Medicare among veterans receiving primary care in community-based and hospital outpatient clinics. Health Serv Res. 2010;45:1268–86.PubMedCentralCrossRefPubMed
34.
go back to reference Liu CF, et al. Reliance on Veterans Affairs outpatient care by Medicare-eligible veterans. Med Care. 2011;49:911–7.CrossRefPubMed Liu CF, et al. Reliance on Veterans Affairs outpatient care by Medicare-eligible veterans. Med Care. 2011;49:911–7.CrossRefPubMed
Metadata
Title
Clinical and economic burden of community-acquired pneumonia in the Veterans Health Administration, 2011: a retrospective cohort study
Authors
John M. McLaughlin
Maribeth H. Johnson
Stephen A. Kagan
Stephanie L. Baer
Publication date
01-12-2015
Publisher
Springer Berlin Heidelberg
Published in
Infection / Issue 6/2015
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI
https://doi.org/10.1007/s15010-015-0789-3

Other articles of this Issue 6/2015

Infection 6/2015 Go to the issue

Images in Infection

Alopecia syphilitica diffusa

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.